<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464045</url>
  </required_header>
  <id_info>
    <org_study_id>1245-0097</org_study_id>
    <nct_id>NCT03464045</nct_id>
  </id_info>
  <brief_title>Empa PASS on Urinary Tract Malignancies</brief_title>
  <official_title>Post-authorisation Safety Study to Assess the Risk of Urinary Tract Malignancies in Relation to Empagliflozin Exposure in Patients With Type 2 Diabetes: a Multi-database European Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the risk of urinary tract malignancies in patients
      initiating empagliflozin (free or fixed dose combination) compared to patients initiating
      other sodium glucose co-transporter-2 (SGLT-2) inhibitors and to patients initiating a
      dipeptidyl peptidase-4 (DPP-4) inhibitor (2 separate comparison groups).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 16, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>occurance of urinary tract cancer</measure>
    <time_frame>upto 60 months</time_frame>
    <description>first incidence of urinary cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>occurance of bladder cancer</measure>
    <time_frame>upto 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>occurance of renal cancer</measure>
    <time_frame>upto 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurance of other urinary tract cancers</measure>
    <time_frame>upto 60 months</time_frame>
    <description>non-renal, non- urinary bladder, urinary tract cancers</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">4500</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>type 2 diabetes patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empagliflozin</intervention_name>
    <description>drug</description>
    <arm_group_label>type 2 diabetes patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT-2 inhibitors</intervention_name>
    <description>drug</description>
    <arm_group_label>type 2 diabetes patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DPP-4 inhibitors</intervention_name>
    <description>drug</description>
    <arm_group_label>type 2 diabetes patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is an observational, comparative, cohort safety study based on European healthcare
        databases and includes databases from the UK and Sweden.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes

          -  Age over 18 years at index date

          -  At least 1 year of membership in the medication database prior to index date

        Exclusion Criteria:

          -  Patients with any cancer (excluding non-melanoma skin cancer) recorded at any time
             prior to the index date (i.e. during the available look-back time)

          -  Diagnosis of type 1 diabetes or other specific non-type 2 diabetes

          -  Use of a SGLT-2 inhibitor or a DPP-4 inhibitor recorded at any time prior to index
             date (i.e. during the available look-back time)

          -  Use of fixed-dose combinations of SGLT-2 inhibitors with DPP-4 inhibitors

          -  Diagnosis of end stage renal disease or receipt of renal dialysis recorded at any time
             prior to index date (i.e. during the available look-back time)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasi Korhonen, 358-50-3652990</last_name>
    <role>Principal Investigator</role>
    <affiliation>pasi.korhonen@epidresearch.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Swedish prescribed drug register</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Kingdom Clinical Practice Research Datalink (CPRD)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

